Predictors of Outcome and Hemorrhage in Patients Undergoing Endovascular Therapy with Solitaire Stent for Acute Ischemic Stroke

Shaowei Jiang, Aihua Fei, Ya Peng, Jun Zhang, You-ran Lu, Hai-rong Wang, Miao Chen, Shuming Pan

1 Emergency Department, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China, 2 Cerebral Vascular Disease Center, The First People’s Hospital of Changzhou, Soochow University, Changzhou, 213003, China, 3 Department of Medical Imaging, The First People’s Hospital of Changzhou, Soochow University, Changzhou, 213003, China

☯ These authors contributed equally to this work.
* shumingpan@163.com

Abstract

Background
Endovascular mechanical thrombectomy is emerging as a promising therapeutic approach for acute ischemic stroke and show some advantages. However, the data of predicting clinical outcome after thrombectomy with Solitaire retriever were limited. We attempt to identify prognostic factors of clinical outcome in patients with acute ischemic stroke undergoing thrombectomy with Solitaire retriever.

Methods
We conducted a retrospective analysis of consecutive acute ischemic strokes cases treated between December 2010 and December 2013 where the Solitaire stent retriever was used for acute ischemic stroke. We assessed the effect of selected demographic characteristics, clinical factors on poor outcome at 3 months (modified Rankin score 3–6), mortality at 3 months, and hemorrhage within 24 h (symptomatic and asymptomatic). Clinical, imaging and logistic variables were analyzed. A multivariate logistic regression analysis was used to identify variables influencing clinical outcome, based on discharge NIHSS score change and mRS at 3 months.

Results
Eighty nine consecutive patients with acute ischemic stroke underwent mechanical thrombectomy. Multivariate analysis revealed that admission NIHSS score, Serum glucose and endovascular procedure duration were independently associated with clinical outcome. Sex, NIHSS score at admission, diabetes and time of operation were associated with sICH in 1 day. NIHSS score ≥20 (OR 9.38; 95% CI 2.41–36.50), onset to reperfusion >5 hours (OR 5.23; 95% CI 1.34–20.41) and symptomatic intracranial hemorrhage (OR 10.19; 95% CI 1.80,57.83) were potential predictive factors of mortality at 3 months.
Conclusion

Multiple pre- and intra-procedural factors can be used to predict clinical outcome, symptomatic intracranial hemorrhage and mortality in acute ischemic stroke patients undergoing endovascular therapy. This knowledge is helpful for patients selection for endovascular mechanical thrombectomy.

Introduction

Arterial reperfusion is considered as the main criterion of successful early management of acute ischemic stroke (AIS). Intravenous (IV) thrombolysis and endovascular thrombectomy are two major strategies to achieve recanalization. Although IV recombinant tissue plasminogen activator (rt-PA) is the approved treatment for AIS, the narrow time window and high number of exclusion criteria limit its applications [1,2]. Endovascular mechanical thrombectomy reaches higher rate of recanalization and good clinical outcome, has longer applying time window compared with IV thrombolysis [3,4]. Moreover, patients treated with new stent device, SOLITAIRE FR, shows higher revascularization rate and better neurological outcome compared with the earlier generation device (Merci Retriever, Stryker Neurovascular) [5,6]. Furthermore, recent studies indicate that rapid thrombectomy treatment after stroke onset resulted in higher reperfusion rate, better functional recovery and similar safety compared with IV rt-PA treatment [7–9].

Solitaire stent device provides us the fast and technically simple reperfusion resolution. However, limited data are available regarding predictors of outcome after thrombectomy with this third generation device [10]. It is important to identify criteria for patients likely to benefit from thrombectomy in order to improve selection and subsequently clinical prognosis. Therefore, we retrospectively evaluated the medical history and clinical data of 89 consecutive patients with symptomatic AIS treated with the Solitaire™ FR device (ev3/Covidien, Irvine, CA, USA) at our institution in a 35-month period. We attempted to identify notable factors predicting poor outcome, symptomatic intracranial hemorrhage (sICH) and death in patients with AIS undergoing mechanical thrombectomy with solitaire stent retriever.

Patients and Methods

This retrospective study had been approved by Ethics Committee of the The First People’s Hospital of Changzhou, Soochow University. As the protocol used in this study is a method approved by the local Institutional Review Board, the requirement for individual patient consent or consent of their relatives was waived, and informations of patients were anonymized prior to analysis. We retrospectively analyzed the angiographic and clinical data of 89 consecutive patients with acute ischemic stroke due to large vessel occlusion who were treated with Solitaire FR stent either alone or in combination with application of thrombolytic drugs, balloon angioplasty or stent-assisted angioplasty in The First People’s Hospital of Changzhou, Soochow University between December 2010 and December 2013. The baseline NIHSS score, a clinical measure of neurologic deficit with a range of 0 (no deficit) to 42 (maximum possible deficit), was used to identify patients with a score of 10 or more, who have a greater than 80% likelihood of a major arterial occlusion [11]. The main inclusion criteria were: NIHSS score ≥10; treatment performed within 6 h from the onset of symptoms and no large hypodensity on CT or multimodal MRI; and occlusion of a major cerebral artery on the cranial CT, CTA or...
MRA. When vessel imaging was unavailable, NIHSS score ≥10, coma, hemiplegia, tetraparesis and aphasia were used as the proximal occlusion criteria.

Key exclusion criteria included uncontrolled hypertension, serious sensitivity to radiographic contrast agents, and CT or MRI evidence of intracranial hemorrhage or major ischemic infarction (acute ischemic change in more than a third of the middle cerebral artery territory or more than 100 mL of tissue in other territories) [5].

On admission, a stroke neurologist examined all patients clinically. Cranial CT or multimodal MRA were obtained prior to every intervention to confirm the diagnosis of large vessel occlusion and to rule out intra-cranial hemorrhage. Interventional treatment was initiated within 6 hours from onset of stroke symptoms.

The following data were collected: age, gender, cerebrovascular risk factors, baseline functional level prior to stroke onset (according to modified Rankin Scale, mRS), admission National Institutes of Health Stroke Scale (NIHSS) score, time of symptom onset. Technical details of the endovascular procedure that were collected included time from symptom onset to femoral artery puncture, Solitaire FR stent size, number of retrieval passes, and use of other intraarterial devices and pharmacologic agents.

Procedural factors that were captured included time to procedure from symptom onset, procedure duration, location of the vascular occlusion, presence of collateral support, and degree of recanalization based on the thrombolysis in cerebral infarction (TICI) scoring system. TICI grade 0 was defined as no perfusion; grade 1 was defined as perfusion past the initial obstruction but limited distal branch filling with little or slow distal perfusion; grade 2a was defined as perfusion of <1 of the vascular distribution of the occluded artery; grade 2b was defined as perfusion of greater than two thirds of the vascular distribution of the occluded artery; and grade 3 was defined as full perfusion with complete filling of all distal branches (some delay was accepted in the presence of proximal vasospasm or competitive collateral flow) [12]. Successful recanalization of the middle cerebral artery required reperfusion through all M1 and M2 segments. Successful recanalisation of internal carotid artery terminus lesions required reperfusion through the internal carotid artery and all M1 and M2 branches. Successful recanalization of a vertebral artery required reperfusion through both the target vertebral artery and the basilar artery.

Intracranial hemorrhagic transformations, were divided into clinically silent or symptomatic, and then classified into different categories. Hemorrhage was scored using the Pessin criteria and formalized in the ECASS trials (hemorrhagic infarction, types 1 and 2; parenchymal hematoma, types 1 and 2 [13–15]. Symptomatic intracranial hemorrhage was defined as any parenchymal hematoma subarachnoid hemorrhage, or intraventricular hemorrhage associated with a worsening of the NIHSS score by four or more within 24 h [5].

Stroke mechanism according to the TOAST classification, subtypes of acute ischemic stroke were defined at the 3-month follow-up as follows: cardioembolic, large vessel atherosclerosis, other (uncommon etiologies), or undetermined [16]. When no etiology was found or when two diagnoses were possible, the etiology was classified as undetermined.

Functional dependence was defined as a score of 3 to 6 on the modified Rankin Scale at 90 days. Functional independence was defined as a score of 0 to 2 on the modified Rankin Scale at 90 days.

**Statistical Methods**

Quantitative variables were described as mean and standard deviation and qualitative data as number and percentage. SPSS for windows statistical software (Version 16.0; SPSS Inc., Chicago, IL, USA) was used for *t*-TEST and Chi-2 test analyses. Univariate logistic regression and
multivariate (step wise logistic regressions, with enter and removal limits set at 0.10 and factors significant at $p = 0.05$ included) analyses were performed to determine factors associated with poor functional outcome at 3 months, mortality at 3 months and hemorrhage at 1 day. A $p$ value $<0.05$ was considered significant. Odds-ratio (OR) and their 95% confidence intervals were calculated. Regression statistical tests were performed using SAS version 9.4 statistical software (SAS Inc., Cary, NC, USA).

**Results**

**Population baseline**

Fifty five men and 34 women were retrospective included with a mean age of 63 (range 21–85) years and a mean initial NIHSS score of 19 (range 10–34). Of 89 patients in this study, 44 patients suffered atrial fibrillation, 13 patients suffered diabetes mellitus and 26 patients with hypertension. Causes of stroke were cardiogenic embolism in 42 patients (47.2%), large-artery atherosclerosis in 39 patients (43.8%). Other or undetermined reasons for stroke was happened in 5 (5.6%) and 3 (3.4%) patients respectively. The occlusion involved the anterior circulation in 81 (91%) patients, posterior circulation in 7 patients and anterior plus posterior circulation in one patient. There were 17 patients (19.1%) with arterial stenosis and 4 patients (5.6%) with arterial dissection. Detailed baseline and clinical characteristics of these patients were shown in Table 1.

**Thrombectomy data and results**

The mean time between symptom onset to operation was 171 min (range 60–356), and mean value of time from needle to recanalization was 115 min (range 49–420). The total time between onset to recanalization ranged from 120 min to 660 min, with a mean value of 285 min. Mean passes of the thrombectomy device used on each patient were 2.19 (range 1–6). Thirty two patients (36.0%) only received Solitaire stent treatment, 25 patients were treated with combination of stent and urokinase, 27 (30.0%) and 2 (2.2%) patients used Solitaire FR together with balloon and aspiration device (Penumbra) respectively. Decompressive craniectomy was applied on 12 patients (13.5%), and 28 patients (31.5%) suffered stent-assisted angioplasty. More details were showed in Table 2.

**Clinical results**

As shown in Table 3, total recanalization rate was achieved in 67.4%, with TICI3 rate of 39.3% and TICI2b rate 28.1%. Clinical efficacy (mRS 0–2) at 3 months was achieved for 41.6% (37/89). Sixty-eight (76.4%) patients showed improvement of clinical symptoms (NIHSS ≥ 4) at discharge, with 14 patients (15.7%) complete recovery. All patients underwent a follow-up CT scan within 1 day when neurological status worsened. Infarction hemorrhagic transformation occurred in 42 (47.2%), with the the following subtypes: 10 (11.24%) asymptomatic hemorrhagic infarction type (HI) 1, 13 (14.6%) asymptomatic HI2, 4 (4.5%) asymptomatic parenchymal hemorrhage type (PH) 1, 4 (4.5%) asymptomatic PH2, 11 (12.4%) symptomatic intracranial hemorrhage (sIHC).

**Prognostic factors for clinical outcome**

Only three independent prognostic factors for clinical outcome were identified under multivariate logistic regression analysis, while nine factors showed significant association with functional recovery on univariate analysis (Table 4). Baseline NIHSS score (multivariate analysis OR 5.25, 95% CI 1.66–16.63), serum glucose (multivariate analysis OR 1.31, 95% CI 1.06–1.63) and time from needle to recanalization (multivariate analysis OR 2.97, 95% CI 1.00–8.83) were
Table 1. Baseline of clinical and neuroimaging characteristics of population.

| Demographics                                      | Value(n, % Unless Otherwise Specified) |
|---------------------------------------------------|----------------------------------------|
| Age (years), mean ± SD                            | 63.12±13.98(21–85)                     |
| Sex (male: female)—no.(%)                         | (55:34)(61.80%-38.20%)                |
| NIHSS score on admission, mean ± SD               | 19.17±4.64(10–34)                      |
| NIHSS score on admission, median                  | 19                                     |
| NIHSS score at discharge                          | 10.52±11.09(0–42)                      |
| Cerebrovascular risk factors                      |                                        |
| Atrial fbrillation                                | 44(49.44%)                             |
| Coronary artery disease or myocardial infarction  |                                        |
| Diabetes mellitus                                 | 13(14.61%)                             |
| Serum glucose, mmol/l mean±(SD) (range)           | 7.97±3.57(3.9–20)                      |
| Hypertension                                      | 26 (47.3%)                             |
| Blood Pressure, mmHg mean±(SD) (range)            |                                        |
| Systolic                                          | 136.48±24.34 (87–192)                  |
| Diastolic                                         | 80.39±13.86 (52–112)                   |
| TG>2.02mmol/l—no.(%)                              | 5(9.1)                                 |
| Triacylglycerol, mmol/l mean±(SD) (range)         | 1.79±0.98 (0.68–4.71)                  |
| TC>5.7mmol/l—no.(%)                               | 13(23.6)                               |
| Cholesterol, mmol/l mean±(SD) (range)             | 4.40±0.89 (2.19–6.89)                  |
| Stroke cause on day 7—no. (%)                     |                                        |
| Cardiogenic embolism                              | 42(47.19%)                             |
| Large-artery atherosclerosis                      | 39(43.82%)                             |
| Other                                             | 5(5.62%)                               |
| Undetermined                                      | 3(3.37%)                               |
| Distribution of vascular occlusion, stenosis and dissection |                           |
| Anterior circulation                              | 81(91.01%)                             |
| MCA M1/M2                                         | 62(69.67%)                             |
| ACA A1/A2                                         | 2(2.25%)                               |
| ICA                                               | 4(4.49%)                               |
| Tandem occlusion (ICA1 MCA M1/M2)                 | 13(14.61%)                             |
| Posterior circulation                             | 7(7.87%)                               |
| Basilar                                           | 4(4.49%)                               |
| vertebral                                        | 1(1.12%)                               |
| Tandem occlusion(vertebral+ Basilar, Basilar+ PCA P1/ P2) | 2(2.25%)                             |
| Anterior and posterior circulation                | 1(1.12%)                               |
| Site of Stenosis                                  | 17(19.10)                              |
| MCA—no.(%)                                        | 13(14.61)                              |
| ICA—no.(%)                                        | 2(2.25)                                |
| BA—no.(%)                                         | 2(2.25)                                |
| Site of Dissection                                | 5(5.62)                                |
| ICA—no.(%)                                        | 4(4.49)                                |
| VA—no.(%)                                         | 1(1.12)                                |

doi:10.1371/journal.pone.0144452.t001
significantly associated with outcomes in both univariate and multivariate regression analysis. Additionally, sex (OR 4.23, 95% CI 1.63–10.98), 7th NIHSS score (OR 1.82, 95% CI 1.38–2.39), diabetes (OR 10.80, 1.34–87.23), blood pressure (systolic pressure OR 1.02, 95% CI 1.00–1.03; diastolic pressure OR 1.03, 95% CI 1.00–1.07) and atrial fibrillation (OR 2.72, 95% CI 1.14–6.52) showed correlation with 3 month outcome only on univariate analysis (Table 4).

Table 2. Data of mechanical thrombectomy with Solitaire.

| Demographics | Value(n, % Unless Otherwise Specified) |
|--------------|----------------------------------------|
| Onset to needle, min mean±(SD)(range) | 170.64 ±67.73 (60–356) |
| Door to needle, min mean±(SD)(range) | 69.2±32.44 (30–180) |
| Needle to recanalization, min mean±(SD)(range) | 114.51±63.65 (49–420) |
| Onset to recanalization, min mean±(SD)(range) | 285.15±94.23 (120–660) |
| Number of passes with Solitaire FR mean±(SD)(range) | 2.19±1.20 (1–6) |
| 1 | 3 (37.08%) |
| 2 | 2 (23.60%) |
| 3 | 2 (25.84%) |
| >3 | 2 (13.48%) |

Multimodal endovascular therapy

| Solitaire FR only | 32 (35.96%) |
| IA urokinase—no.(%) | 25 (28.09%) |
| Dose of urokinase 10,000 IU mean±(SD)(range) | 274194±123741 (100000–550000) |
| Balloon—no.(%) | 27 (30.3%) |
| Stent-assisted angioplasty—no.(%) | 28 (31.46%) |
| Decompressive craniectomy—no.(%) | 12 (13.48%) |
| Aspiration thrombectomy with Penumbra | 2 (2.24%) |

doi:10.1371/journal.pone.0144452.t002

Table 3. Outcome after endovascular thrombectomy treatment.

| Demographics | Value(n, % Unless Otherwise Specified) |
|--------------|----------------------------------------|
| TICI recanalization | | |
| 0 | 6 (6.74%) |
| 1 | 5 (5.62%) |
| 2a | 18 (20.22%) |
| 2b | 25 (28.09%) |
| 3 | 35 (39.33%) |
| Success of recanalization—no.(%) | 78 (87.64%) |
| Complete recanalization (TICI 3)—no.(%) | 35 (39.33%) |
| Partial recanalization (TICI 2a/2b)—no.(%) | 43 (48.31%) |
| Recanalization failure (TICI 0/1)—no.(%) | 11 (12.36%) |
| Improvement of clinical symptom—no.(%)(NIHSS ≥4) | 68 (51.96%) |
| Complete recovery (NIHSS = 0)—no.(%) | 14 (15.73%) |
| mRS ≤ 2 at 90 days—no.(%) | 37 (41.57%) |
| Infarction Haemorrhagic Transformation—no.(%) | 42 (47.2%) |
| Asymptomatic HI-1—no.(%) | 10 (11.24%) |
| HI-2—no.(%) | 13 (14.61%) |
| PH-1—no.(%) | 4 (4.49%) |
| PH-2—no.(%) | 4 (4.49%) |
| Symptomatic PH-2—no.(%) | 7 (7.87%) |
| IVH—no.(%) | 4 (4.49%) |

doi:10.1371/journal.pone.0144452.t003
Prognostic factors for sICH

Female (OR 8.50, 95% CI 1.71–42.17), increased admission (OR 7.60, 95% CI 1.54–37.64) and 7th day (OR 1.09, 95% CI 1.03–1.15) NIHSS scores, diabetes (OR 7.29, 95% CI 1.81–29.40), serum glucose (OR 1.25, 95% CI 1.07–1.47), and increased time from needle to recanalization (OR 1.01, 95% CI 1.00–1.01) were associated with sICH in the univariate analysis. On the multivariable analysis, Female (OR 10.34, 95% CI 1.34–79.59), increased admission NIHSS scores (OR 9.73, 95% CI 1.34–70.69), diabetes (OR 7.34, 95% CI 1.32–40.84) and increased time from needle to recanalization (OR 1.01, 95% CI 1.00–1.02) remained significantly associated with sICH. The final multivariable model is shown in Table 5.

Prognostics factors for mortality

Of 89 cases, 21 patients (23.6%) were deceased at 3 months, 13 patients (14.6%) had malignant cerebral edema, and 8 patients (9.0%) had sICH. Both univariate and multivariate logistic regression analysis were performed to identify mortality prognostic factors. Symptomatic ICH (OR 10.19, 95% CI 1.80–57.83) and admission NIHSS score (OR 9.38, 95% CI 2.41–36.50) were important prognostic factors of death. Interestingly, the time of symptoms onset to recanalization (OR 1.01, 95% CI 1.00–1.02) showed a significant association with mortality under multivariate analysis. Moreover, other six independent prognostic factors of mortality, including increased age (≥ 70 OR 3.59, 95% CI 1.01–12.73) and 7th day NIHSS scores (OR 1.30, 95% CI 1.16–1.44), higher serum glucose (OR 1.17, 95% CI 1.03–1.33), multiple affected hemisphere baseline image (OR 4.65, 95% CI 1.13–19.21), 2 passes with Solitaire FR (OR 4.46, 95% CI 1.14–17.50) and needle to recanalization (OR 1.01, 95% CI 1.00–1.02), also were identified.
by univariate logistic regression analysis. Results of the univariate and multivariate analysis of potential factors predictive of mortality at 3 months are detailed in Table 6.

## Discussion

According to the newest American Heart Association/American Stroke Association (AHA/ASA) guidelines for early management of patients with AIS, endovascular thrombectomy with the third generation stent has been proved to an important strategy to manage AIS[17]. Here, we presented our single-center retrospective study about Chinese AIS patients treated with mechanical thrombectomy. We focus on identifying prognostic factors for not only clinical outcomes but also sICH after endovascular treatment with Solitaire. At 3 months, the independent prognostic factors for clinical outcome were NIHSS score on admission, serum glucose and time from needle to recanalization. Prognostics for mortality after 3 month were NIHSS score on admission, time from symptom onset to recanalization and sICH. Sex, NIHSS score on admission, diabetes and time from needle to recanalization were associated with sICH in 1 day.

### Comparison with other Solitaire studies

Here, we showed our endovascular treatment data from single center. In comparison with other thrombectomy studies, little lower recanalization rate (67.4%) was observed, but clinical efficac (41.6%) was similar with these trails [5,7,18–20]. With respect to previous study, a slightly higher sICH rate (12.4%) and mortality (23.6%) probably were due to the different selection criteria in terms of admission NIHSS score or other variants [5,8,20,21].

The predictors of AIS patients treated with Solitaire stent are variable in different studies. In Soize’s study, the angiography data, ASPECT score, was the important predictor for clinical outcome, mortality and sICH, and thrombus length, recanalization and endovascular procedure time were associated with clinical outcome[22]. Another study about French AIS patients showed the prognostic factors for outcome were age, sex, site of occlusion and initial NIHSS score[19]. Recanalization time and FLAIR negativity were associated with clinical outcome in Raoult’s study, while Costalat et al found hyperglycemia and baseline NIHSS score could

### Table 5. Analysis of potential factors predicting symptomatic intracranial hemorrhage (sICH) at day 1.

| Factors                          | No sICH | sICH | Univariate analysis OR(95%CI) | Multivariate analysis OR(95%CI) |
|----------------------------------|---------|------|------------------------------|---------------------------------|
| Sex                              |         |      |                              |                                 |
| Male                             | 51(65.38) | 2(18.18) | 1                            | 1                              |
| Female                           | 27(34.62) | 9(81.82) | 8.50(1.71,42.17)             | 10.34(1.34,79.59)              |
| NIHSS score on admission         |         |      |                              |                                 |
| <20                              | 49(62.82) | 2(18.18) | 1                            | 1                              |
| ≥20                              | 29(37.18) | 9(81.82) | 7.60(1.54,37.64)             | 9.73(1.34,70.69)              |
| NIHSS 7, mean±SD                 | 8.92±10.57 | 21.82±7.87 | 1.09(1.03,1.15) | –                             |
| Diabetes                         |         |      |                              |                                 |
| No                               | 70(89.74) | 6(54.55) | 1                            | 1                              |
| Yes                              | 8(10.26)  | 5(45.45) | 7.29(1.81,29.40)             | 7.34(1.32,40.84)              |
| Serum glucose, mean±SD           | 7.66±3.62 | 12.32±4.10 | 1.25(1.07,1.47) | –                             |
| Needle to recanalization, mean±SD| 110.92±54.16 | 139.91±110.66 | 1.01(1.00,1.01) | 1.01(1.00,1.02) |
| Onset to recanalization          |         |      |                              |                                 |
| <5H                              | 41(52.56) | 6(54.55) | 1                            | –                             |
| ≥5H                              | 37(47.44) | 5(45.45) | 0.92(0.26,3.28) | –                             |

doi:10.1371/journal.pone.0144452.t005
predict the clinical outcome [10,21]. In our study, we found initial NIHSS score, hyperglycemia and endovascular procedure time associated with clinical outcome, but no angiography data prognostic factors were observed. The different studies concluded different predictors might be caused by patient population difference, or whole treatment procedure variance, or some other statistic factors such as limited patients.

**NIHSS score at admission**

NIHSS score is a quick and relatively simple guide to estimate the extent and the severity of stroke, and the newest guideline point out that NIHSS > 6 is an important patient selection criteria for thrombectomy treatment [17,23]. In this study, baseline NIHSS score of all the stroke patients were above 10. As NIHSS score is the most powerful predictor for long-term outcome of patients with AIS [24], we also found it associated with clinical outcome, mortality and sICH in the present cohort. Lower NIHSS score (NIHSS < 20) showed significant association with favor outcomes (OR 5.25). Patients with admission NIHSS score ≥ 20 only showed 21.1% (8/38) clinical efficacy, while functional recovery rate was 56.9% (29/51) in less severe stroke patients (NIHSS < 20). However, it does not mean mechanical thrombectomy is not recommended on patients with high score of admission NIHSS, and rapid arterial reperfusion still is an effective strategy on severe stroke patients [25]. Actually, endovascular treatment for patients suffered moderate or severe stroke (NIHSS > 15 or NIHSS ≥ 20) showed great potential versus intravenous thrombolysis [26–28].

### Table 6. Analysis of potential factors predictive of mortality at 3 months.

| Factors                                           | Death       | Alive       | Univariate analysis OR(95%CI) | Multivariate analysis OR(95%CI) |
|---------------------------------------------------|-------------|-------------|-----------------------------|--------------------------------|
| **Age**                                           |             |             |                             |                                |
| <60                                               | 4(19.05)    | 30(44.12)   | 1                           |                                |
| 60–70                                             | 6(28.57)    | 15(22.06)   | 3.00(0.73,12.27)             |                                |
| >70                                               | 11(52.38)   | 23(33.82)   | 3.59(1.01,12.73)             |                                |
| **NIHSS score on admission**                       |             |             |                             |                                |
| <20                                               | 4(19.05)    | 47(69.12)   | 1                           | 1                              |
| ≥20                                               | 17(80.95)   | 21(30.88)   | 9.51(2.85,31.73)             | 9.38(2.41,36.50)               |
| **NIHSS 7,means±SD**                              |             |             |                             |                                |
| <20                                               | 4(19.05)    | 47(69.12)   | 1                           |                                |
| ≥20                                               | 17(80.95)   | 21(30.88)   | 9.51(2.85,31.73)             |                                |
| **Serum glucose,means±SD**                        |             |             |                             |                                |
| <20                                               | 4(19.05)    | 47(69.12)   | 1                           |                                |
| ≥20                                               | 17(80.95)   | 21(30.88)   | 9.51(2.85,31.73)             |                                |
| **Affected hemisphere on baseline imaging**        |             |             |                             |                                |
| Left_hemisphere                                   | 8(38.10)    | 31(45.59)   | 1                           |                                |
| Right_hemisphere                                  | 7(33.33)    | 32(47.06)   | 0.85(0.27,2.62)              |                                |
| Multiple                                          | 6(28.57)    | 5(7.35)     | 4.65(1.13,19.21)             |                                |
| **Number of passes with Solitaire FR**             |             |             |                             |                                |
| 1                                                 | 4(19.05)    | 29(42.65)   | 1                           |                                |
| 2                                                 | 8(38.10)    | 13(19.12)   | 4.46(1.14,17.50)             |                                |
| 3                                                 | 6(28.57)    | 17(25.00)   | 2.56(0.63,10.37)             |                                |
| >3                                                | 3(14.29)    | 9(13.24)    | 2.42(0.45,12.88)             |                                |
| **Needle to recanalization,means±SD**             |             |             |                             |                                |
| <5H                                               | 7(33.33)    | 40(58.82)   | 1                           | 1                              |
| ≥5H                                               | 14(66.67)   | 28(41.18)   | 2.86(1.02,7.99)              | 5.23(1.34,20.41)               |
| **Infarction Haemorrhagic Transformation**         |             |             |                             |                                |
| NO_sICH                                           | 13(61.90)   | 65(95.59)   | 1                           |                                |
| sICH                                              | 8(38.10)    | 3(4.41)     | 13.33(3.11,57.09)            | 10.19(1.80,57.83)              |

doi:10.1371/journal.pone.0144452.t006
Sex

Sex is a controversial factor predicting AIS outcomes. In our study, sex appeared correlated with functional outcome under univariate regression analysis, however, did not significantly associate with clinical outcome on multivariate analysis. This is in accordance with the previous result of association analysis on sex and thrombolysis outcome[29,30]. In Hametner’s study, sex was no longer the prognostic factor even on the univariate analysis after matching other factors (such as age, NIHSS score et al.) for the female and male patients[29]. Interestingly, age and prevalence rate of atrial fibrillation were significantly higher in female patients than males in our cohort (Table 7). Age was considered as prognostic factors in other studies [21,31], though it did not associate with functional outcomes in the present study. Furthermore, atrial fibrillation was an independent prognostic factor in our univariate regression analysis (Table 4), and female atrial fibrillation patients with stroke usually were suggested worse outcome [32,33]. Consequently, that sex was considered as prognostic factors for clinical outcome might be contributed from the difference in age and incidence of atrial fibrillation.

Although sex was not the prognostic factor for clinical outcome, female predicted higher frequency of sICH both before and after adjusted in our cohort. On the coarsened exact matching study, sex was obviously associated with sICH in stroke thrombolysis[29]. But, whether dose of rt-PA effected the association between sex and sICH was still not clear in their research [29]. As the frequency and dose of urokinase administered to stroke patients did not show significant difference between male and female (Table 7), the effect of thrombolytic agents was excluded in our endovascular thrombectomy study. However, we could not eliminate the interference of imbalanced age and atrial fibrillation distribution on the correlation of sex and sICH.

Serum glucose and diabetes

Hyperglycemia is a common feature of acute stroke, and admission hyperglycemia in ischemic stroke patients often associated with worse prognosis and higher mortality[34–36]. Hyperglycemia was considered as an epiphenomenon of acute stress response, and might aggravate cerebral damage[37–39]. Hyperglycemia also impaired recanalization and decreased reperfusion rate in patients treated with intravenous thrombolysis[40]. Although the recanalization rate was in a relatively high level and reperfusion time was not affected by hyperglycemia in our study, we found blood glucose was helpful to predict the clinical outcome. Some other negative effects of hyperglycemia, such as increased reperfusion injury, might still lead to bad outcomes.

It is inconclusive whether ischemic stroke patients with diabetes have worse functional recovery till now[40]. Therefore, it was not surprised that diabetes was not associated with clinical outcome in our multivariate analysis, even if diabetes predicted worse outcome under univariate regression analysis (Table 4). This result was consistent with some recent thrombectomy trials[10,19,21,41]. On the other hand, diabetes is a condition of accelerated vascular aging and a risk factor for intracerebral hemorrhage[42,43]. We presented more than 7 fold risk of sICH in patients with diabetes compared with non-diabetes group both in univariate analysis and multivariate models. In accordance with our finding, we emphasize that more attention should be paid to control sICH when endovascular thrombectomy was applied on patients with diabetes.

Time of recanalization

Recanalization is helpful to prevent infarct growth and decreased delay of reperfusion time as possible is emphasized in the newest guideline for AIS patients management[17]. Recent multicenter study with stent retriever also revealed faster procedure time and shorter treatment
delays can lead to better clinical outcomes[25,42]. Reducing delay from image to groin puncture time and shortening endovascular procedure duration for ischemic stroke therapy was likely associated with improved clinical outcome[44]. Correspondingly, the shorter time from needle to recanalization predicted independent functional outcomes and lower sICH rate in our study. It indicated the further potential to improve the endovascular procedure efficiency and perhaps achieve better clinical benefits.

Time from symptoms onset to recanalization also is identified as an important mortality prognostic factor previously[8,25,45]. Not surprisingly, we found time from onset to reperfusion time beyond 5 hours was associated with mortality. The longer time of cerebral ischemic, the severer damage to brain happened. Earlier to hospital, faster determine time and more efficient operation procedure are important to reducing mortality.

Actually, to get better recanalization, we use some other methods, such as balloon angioplasty, stent-assisted angioplasty and injecting urokinase, et al, combined with Solitaire stent during thrombectomy procedure (Table 2). This multimode operation improved the thrombectomy and reperfusion efficiency.

### sICH, clinical outcome and mortality

Symptomatic intracranial hemorrhage often leads to bad outcome[46], however, it did not show significant association with clinical efficacy at 3 months, even in univariate analysis. We proposed that thrombectomy treatment or some other reasons might be benefit for recovery of patients suffered sICH, although hemorrhage made symptomatic more severe temporarily. Nevertheless, sICH increased the odds (more than 10 fold) of death in our regression model. This warn us sICH still is a severe complication and we should keep enough coping strategies when thrombectomy proceeded.

### Table 7. Factors distributed between female and male.

|                      | Male           | Female         | Test | P value |
|----------------------|----------------|----------------|------|---------|
| Age (mean±SD)        | 59.5 ± 14.5    | 68.4 ± 11.5    | T-test | 0.003** |
| NIHSS score on admission (mean±SD) | 18.4 ± 5.5    | 19.8 ± 4.5    | T-test | 0.223   |
| IA urokinase         |                |                |      |         |
| Yes                  | 20             | 11             | Chi-2 | 0.485   |
| No                   | 33             | 25             | Chi-2 | 0.485   |
| Dose of urokinase (x 1,000 IU) mean±SD | 10.47 ± 15.91 | 8.19 ± 13.64 | T-test | 0.485   |
| Diabetes             |                |                |      |         |
| Yes                  | 5              | 8              | Chi-2 | 0.094   |
| No                   | 48             | 28             | Chi-2 | 0.240   |
| Serum glucose (mean±SD) | 7.80 ± 4.19   | 8.82 ± 3.48    | T-test | 0.784   |
| Hypertension         |                |                |      |         |
| Yes                  | 31             | 20             | Chi-2 | 0.007** |
| No                   | 22             | 16             | Chi-2 | 0.007** |
| Atrial fibrillation  |                |                |      |         |
| Yes                  | 20             | 24             | Chi-2 | 0.007** |
| No                   | 33             | 12             | Chi-2 | 0.007** |
| Onset to needle (mean±SD) | 175.5 ± 64.0  | 170.0 ± 86.2   | T-test | 0.735   |
| Needle to recanalization (mean±SD) | 117.0 ± 71.9  | 110.2 ± 51.2   | T-test | 0.633   |
| Onset to recanalization (mean±SD) | 290.9 ± 101.8 | 280.2 ± 88.3   | T-test | 0.617   |

** indicated significant difference.

doi:10.1371/journal.pone.0144452.t007
In summary, this retrospective study on AIS patients underwent endovascular thrombectomy not only point out some pre- and intra-procedural factors for predicting clinical outcome, sICH and mortality, but also provide some new proofs which are useful for interpreting the controversial prognostic factors (gender, diabetes) of sICH. These knowledges are important when obtaining an informed consent and conveying expectations regarding procedure outcomes, and might be helpful for improving our management of AIS patients.

Our study has several limitations. Limitations of the present study include the retrospective and single-center design. Nevertheless, we had enough statistical power to identify the important predictive factors within our series. Further analyses are needed to determine its importance in the selection of patients for mechanical thrombectomy.

This study is supported by 2013–2014 National Clinical Key Speciality Construction Project, and Science and Technology Commission of Shanghai Municipality grants 13ZR1426500

**Author Contributions**

Conceived and designed the experiments: SJ AF SP. Performed the experiments: SJ YP. Analyzed the data: HW MC. Contributed reagents/materials/analysis tools: SJ AF JZ YL. Wrote the paper: SJ AF.

**References**

1. Grunwald IQ, Wakhloo AK, Walter S, Molyneux AJ, Byrne JV, Nagel S, et al. (2011) Endovascular stroke treatment today. AJNR Am J Neuroradiol 32: 238–243. doi:10.3174/ajnr.A2346 PMID: 21233233

2. Mishra SM, Dykeman J, Sajobi TT, Trivedi A, Almekhlafi M, Sohn SI, et al. (2014) Early reperfusion rates with IV tPA are determined by CTA clot characteristics. AJNR Am J Neuroradiol 35: 2265–2272. doi:10.3174/ajnr.A4048 PMID: 25059699

3. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. (2005) Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36: 1432–1438. PMID: 15961709

4. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. (2008) Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 39: 1205–1212. doi: 10.1161/STROKEAHA.107.510285

5. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. (2012) Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 380: 1241–1249. doi: 10.1016/S0140-6736(12)61384-1 PMID: 22932715

6. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. (2012) Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 380: 1231–1240. doi: 10.1016/S0140-6736(12)61299-9 PMID: 22932714

7. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372: 11–20. doi: 10.1056/NEJMoa1411587 PMID: 25517348

8. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372: 1019–1030. doi: 10.1056/NEJMoa1414905 PMID: 25671798

9. Campbell BC, Mitchell PJ, Kleinitz TJ, Dewey HM, Churilov L, Yassi N, et al. (2015) Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 372: 1009–1018. doi: 10.1056/NEJMoa1414792 PMID: 25671797

10. Costalat V, Lobotesis K, Machi P, Mourad I, Maldonado I, Heroum C, et al. (2012) Prognostic factors related to clinical outcome following thrombectomy in ischemic stroke (RECOStud). 50 patients prospective study. Eur J Radiol 81: 4075–4082. doi: 10.1016/j.ejrad.2012.07.012 PMID: 22940230

11. Lewandowski CA, Frankel M, Tompkins TA, Broderick J, Frey J, Clark W, et al. (1999) Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30: 2598–2605. PMID: 10582984
12. Pereira VM, Gralla J, Davalos A, Bonafe A, Castano C, Chapot R, et al. (2013) Prospective, multicenter, single-arm study of mechanical thrombectomy using Solitaire Flow Restoration in acute ischemic stroke. Stroke 44: 2802–2807. doi: 10.1161/STROKEAHA.113.001232 PMID: 23908066

13. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017–1025. PMID: 7563451

14. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352: 1245–1251. PMID: 9788453

15. Pessin MS, Teal PA, Caplan LR (1991) Hemorrhagic infarction: guilt by association? AJNR Am J Neuroradiol 12: 1123–1126. PMID: 1763738

16. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41. PMID: 7678184

17. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. (2015) 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke.

18. Koh JS, Lee SJ, Ryu CW, Kim HS (2012) Safety and efficacy of mechanical thrombectomy with solitaire stent retrieval for acute ischemic stroke: a systematic review. Neurointervention 7: 1–9. doi: 10.5469/ neuroint.2012.7.1.1 PMID: 22454778

19. Lefevre PH, Lainay C, Thouant P, Chavent A, Kazemi A, Ricolfi F (2014) Solitaire FR as a first-line device in acute intracerebral occlusion: a single-centre retrospective analysis. J Neuroradiol 41: 80–86. doi: 10.1016/j.neurad.2013.04.001 PMID: 23645838

20. Davalos A, Pereira VM, Chapot R, Bonafe A, Andersson T, Gralla J, et al. (2012) Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke. Stroke 43: 2699–2705. PMID: 22851547

21. Raoult H, Eugene F, Ferre JC, Gentic JC, Ronziere T, Stamm A, et al. (2013) Prognostic factors for outcomes after mechanical thrombectomy with solitaire stent. J Neuroradiol 40: 252–259. doi: 10.1016/j.neurad.2013.04.001 PMID: 23684543

22. Soize S, Barbe C, Kadziolka K, Estrade L, Serre I, Pierot L (2013) Predictive factors of outcome and hemorrhage after acute ischemic stroke treated by mechanical thrombectomy with a stent-retriever. Neuroradiology 55: 977–987. doi: 10.1007/s00234-013-1191-4 PMID: 23645838

23. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: 870–947. doi: 10.1161/STR.0b013e318284056a PMID: 23370205

24. Leigh R, Zaidat OO, Suri MF, Lynch G, Sundararajan S, Sunshine JL, et al. (2004) Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. Stroke 35: 1903–1907. PMID: 15178819

25. Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, et al. (2014) Time to angiographic reperfusion and clinical outcome after acute ischemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol 13: 567–574. doi: 10.1016/S1474-4422(14)70066-3 PMID: 24784550

26. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. (2013) Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368: 893–903. doi: 10.1056/NEJMoai1214300 PMID: 23390923

27. Skagen K, Skjelland M, Russell D, Jacobsen EA (2015) Large-Vessel Occlusion Stroke: Effect of Recanalization on Outcome Depends on the National Institutes of Health Stroke Scale Score. J Stroke Cerebrovasc Dis.

28. Gratz PP, Jung S, Schrøth G, Gralla J, Mordasini P, Hsieh K, et al. (2014) Outcome of standard and high-risk patients with acute anterior circulation stroke after stent retriever thrombectomy. Stroke 45: 152–158. doi: 10.1161/STROKEAHA.113.002591 PMID: 24262328

29. Hametner C, Kellett L, Ringleb PA (2015) Impact of sex in stroke thrombolysis: a coarsened exact matching study. BMC Neurol 15: 10. doi: 10.1186/s12883-015-0262-z PMID: 25865102

30. Lorenzano S, Ahmed N, Falcou A, Mikulik R, Tatlisumak T, Roffe C, et al. (2013) Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register. Stroke 44: 3401–3406. doi: 10.1161/STROKEAHA.113.002908 PMID: 24172579
31. Chindaprasirt J, Sawanyawisuth K, Chattakul P, Limpawattana P, Tiamkao S, Aountri P, et al. (2013) Age Predicts Functional Outcome in Acute Stroke Patients with rt-PA Treatment. ISRN Neurol 2013: 710681. doi:10.1155/2013/710681 PMID: 24171121
32. Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM (2014) Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. Thromb Haemost 111: 385–391. doi:10.1160/TH13-04-0347 PMID: 24305974
33. Roth DL, Haley WE, Clay OJ, Perkins M, Grant JS, Rhodes JD, et al. (2011) Race and gender differences in 1-year outcomes for community-dwelling stroke survivors with family caregivers. Stroke 42: 626–631. doi:10.1161/STROKEAHA.110.595322 PMID: 21257820
34. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21: 518–524. PMID: 9571335
35. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS (1999) Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. Lancet 353: 376–377. PMID: 9950447
36. Desilles JP, Meseguer E, Labreuche J, Lapergue B, Sirimargo G, Gonzalez-Valcarcel J, et al. (2013) Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke 44: 1915–1923. doi:10.1161/STROKEAHA.111.000813 PMID: 23704108
37. Kruyt ND, Biessels GJ, Devries JH, Roos YB (2010) Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol 6: 145–155. doi:10.1038/nrneurol.2009.231 PMID: 2057300
38. Baird TA, Parsons MW, Phan T, Butcher KS, Desmond PM, Tress BM, et al. (2003) Persistent post-stroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 34: 2208–2214. PMID: 12893952
39. Christensen H, Boysen G (2002) Blood glucose increases early after stroke onset: a study on serial measurements of blood glucose in acute stroke. Eur J Neurol 9: 297–301. PMID: 11985639
40. Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ (2012) Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 11: 261–271. doi:10.1016/S1474-4422(12)70005-4 PMID: 22341034
41. Yang Y, Liang C, Zhang Q, Shen C, Ma S, Mao J, et al. (2015) Analysis of prognostic factors of endovascular therapy in 59 patients with acute anterior circulation stroke: A retrospective cohort study—Observational. Int J Surg 16: 36–41. doi:10.1016/j.ijsu.2015.02.013 PMID: 25743387
42. Gray CS, Scott JF, French JM, Alberti KG, O’Connell JE (2004) Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 33: 71–77. PMID: 14695867
43. Hill MD (2014) Stroke and diabetes mellitus. Handb Clin Neurol 126: 167–174. doi:10.1016/B978-0-444-53480-4.00012-6 PMID: 25410221
44. Shi ZS, Liebeskind DS, Xiang B, Ge SG, Feng L, Albers GW, et al. (2014) Predictors of functional dependence despite successful revascularization in large-vessel occlusion strokes. Stroke 45: 1977–1984. doi:10.1161/STROKEAHA.114.005603 PMID: 24876082
45. Smit EJ, Vonken EJ, van Seeters T, Dankbaar JW, van der Schaat IC, Kappelle LJ, et al. (2013) Timming-invariant imaging of collateral vessels in acute ischaemic stroke. Stroke 44: 2194–2199. doi:10.1161/STROKEAHA.111.000675 PMID: 23760216
46. Strbian D, Sairanen T, Meretoja A, Pitkaniemi J, Putaala J, Salonen O, et al. (2011) Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology 77: 341–348. doi:10.1212/WNL.0b013e3182267b8c PMID: 21715707